AAV ‐Based Intracerebral Administration of BDNF Promotes Myelin Repair and Cognitive Improvement After Cuprizone‐Induced Demyelination
Glia · 2025-11 · 73 (11) · 2189-2205
DOI: 10.1002/glia.70058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Glia, online erschienen am 06.08.2025. Verfasst von Yousra El Ouaamari und 14 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Experimental Haematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University o…. Hauptthemen laut MEDLINE: Brain-Derived Neurotrophic Factor, Demyelinating Diseases, Myelin Sheath. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University of Antwerp BOF, European Union's Horizon 2020 Research and Innovation Programme Marie Skłodowska-Curie grant, Fritz-Thyssen Foundation.
Abstract (Originalsprache)
Multiple sclerosis (MS) is a chronic neurological disorder involving immune‐mediated demyelination and neurodegeneration in the central nervous system (CNS). Current therapies primarily target inflammation, with limited strategies to promote remyelination or neural repair. This study explores the therapeutic potential of Brain‐Derived Neurotrophic Factor (BDNF) delivered via an adeno‐associated virus (AAV) vector to enhance remyelination and improve cognitive function in a subchronic cuprizone (CPZ)‐induced demyelination mouse model. Sixty female C57BL/6 mice were used, with half receiving a 7‐week CPZ diet to induce oligodendrocyte loss. After demyelination, mice were treated with AAV‐BDNF, AAV‐eGFP, or saline injections into the corpus callosum (CC), followed by a 5‐week recovery phase. Behavioral assessments revealed improved cognitive performance with BDNF treatment, demonstrated by increased latency in passive avoidance tests. Immunofluorescence analysis showed increased proliferation and maturation of oligodendrocyte progenitor cells, with higher PDGFRα and CC1 markers, alongside elevated MBP. Transmission electron microscopy (TEM) indicated thicker myelin sheaths and a higher percentage of myelinated axons in AAV‐BDNF‐treated mice. Mitochondrial analyses revealed that BDNF treatment preserved mitochondrial integrity, with reduced swelling and improved structural regularity. Inflammatory markers showed no differences in Iba1 but indicated a trend of reduced astrocytic activation with BDNF. These results demonstrate that AAV‐BDNF therapy enhances remyelination, myelin integrity, mitochondrial structure, and cognitive function in a CPZ model, underscoring its potential for treating MS. BDNF‐based strategies may offer innovative avenues to improve neurological recovery and address unmet needs in MS management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Experimental Haematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
- μNEURO Research Centre of Excellence, University of Antwerp, Antwerp, Belgium.
- Bio-Imaging Lab (BIL), University of Antwerp, Antwerp, Belgium.
- Center for Oncology Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium.
- Neurochemistry & Behaviour Group, Experimental Neurobiology Unit (ENU), Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
- Wellcome Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Northern Ireland, UK.
ORCID-Profile: Yousra El Ouaamari, Jorrit De Waele, Jasper Van den Bos, Peter Ponsaerts
Förderung
- University of Antwerp BOF
- European Union's Horizon 2020 Research and Innovation Programme Marie Skłodowska-Curie grant
- Fritz-Thyssen Foundation
- The Leverhulme Trust
- Charcot Foundation
- FWO
- Roche Belgium
- Universiteit Antwerpen
Zitieren
APA
El Ouaamari, Y., Ricciardi, L., van der Heijden, S., Peter, A., De Waele, J., Van den Bos, J., Van Dam, D., Calus, E., Kuhn, S., Marei, W., Dombrowski, Y., Verhoye, M., Ponsaerts, P., Wens, I., & Cools, N. (2025). AAV ‐Based Intracerebral Administration of BDNF Promotes Myelin Repair and Cognitive Improvement After Cuprizone‐Induced Demyelination. Glia, 73(11), 2189-2205. https://doi.org/10.1002/glia.70058
Vancouver
El Ouaamari Y, Ricciardi L, van der Heijden S, Peter A, De Waele J, Van den Bos J, et al. AAV ‐Based Intracerebral Administration of BDNF Promotes Myelin Repair and Cognitive Improvement After Cuprizone‐Induced Demyelination. Glia. 2025;73(11):2189-2205. doi:10.1002/glia.70058
BibTeX
@article{ElOuaamari2025,
author = {El Ouaamari, Yousra and Ricciardi, Leonardo and van der Heijden, Sanne and Peter, Antonia and De Waele, Jorrit and Van den Bos, Jasper and Van Dam, Debby and Calus, Elke and Kuhn, Sarah and Marei, Waleed and Dombrowski, Yvonne and Verhoye, Marleen and Ponsaerts, Peter and Wens, Inez and Cools, Nathalie},
title = {AAV ‐Based Intracerebral Administration of BDNF Promotes Myelin Repair and Cognitive Improvement After Cuprizone‐Induced Demyelination},
journal = {Glia},
year = {2025},
volume = {73},
number = {11},
pages = {2189--2205},
doi = {10.1002/glia.70058}
}
EUVIMED